Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the dosing of the first patient in an open-label Phase II trial using its Canadian partner Repare Therapeutics’ (NASDAQ: RPTX) ATR inhibitor, camonsertib. The trial aims to evaluate the safety and efficacy of various targeted therapies and immunotherapies in patients with unresectable, locally advanced, or metastatic solid tumors that harbor oncogenic mutations. Camonsertib is specifically being tested in this study against tumors with ATM and SETD2 loss-of-function mutations.
This development triggers a USD 40 million payment to Repare Therapeutics, supplementing the initial USD 125 million upfront payment made at the onset of their 2022 collaboration, along with accumulated additional payments totaling USD 13.6 million.
As stated in the press release, Roche is also exploring the potential of camonsertib in a Phase Ib/II study against metastatic non-small cell lung cancer (NSCLC), further expanding the drug’s clinical evaluation.- Flcube.com
